Cytori Therapeutics (CYTX) Given a $4.00 Price Target at Maxim Group

Maxim Group set a $4.00 price target on Cytori Therapeutics (NASDAQ:CYTX) in a research report report published on Tuesday. The firm currently has a buy rating on the biotechnology company’s stock.

Several other brokerages also recently commented on CYTX. Zacks Investment Research downgraded Cytori Therapeutics from a hold rating to a sell rating in a research note on Thursday, November 9th. ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a research note on Friday, February 2nd. Finally, B. Riley restated a hold rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.

Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at $0.32 on Tuesday. The company has a market capitalization of $11.10, a PE ratio of -0.36 and a beta of 3.56. Cytori Therapeutics has a 12 month low of $0.22 and a 12 month high of $2.08.

In related news, major shareholder Ag Postfinance sold 286,982 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total value of $88,964.42. Following the transaction, the insider now owns 5,118,627 shares of the company’s stock, valued at approximately $1,586,774.37. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the transaction, the insider now directly owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 695,767 shares of company stock worth $231,951. 1.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Perkins Capital Management Inc. lifted its position in Cytori Therapeutics by 134.0% in the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after acquiring an additional 1,223,046 shares in the last quarter. Sabby Management LLC lifted its position in Cytori Therapeutics by 28.0% in the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after acquiring an additional 355,504 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after acquiring an additional 275,653 shares in the last quarter. 10.82% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://ledgergazette.com/2018/02/17/cytori-therapeutics-cytx-given-a-4-00-price-target-at-maxim-group.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply